NHD Global
Longevity & Bioregulators · Source-reviewed dossier
Source-Reviewed Research Dossier
FOXO4-DRI is an experimental peptide designed to disrupt FOXO4–p53 interaction in selected senescent cells. The widely cited evidence consists of cultured-cell work and mouse experiments, not validated human treatment outcomes.
Shared values below are consolidated from the current catalog record. They are not independent verification or lot results; the current product specification and lot COA control.
Product identity
Literature reference parameters
Identity safeguard Reference identifiers above describe the literature compound record. The supplied form, formula, molecular weight, purity and storage conditions must be verified against the product-specific specification and lot COA.
A target-to-pathway view grounded in the linked research records.
Reported research findings
Reported outcomes are paired with their experimental model and evidence boundary.
The foundational report tested FOXO4-DRI in senescent cells and naturally aged or chemotherapy-exposed mice.
The study is preclinical and does not define human benefit, dose or long-term safety.
Read the primary studyA later study examined senescent-cell clearance and testosterone-related measures in naturally aged male mice.
A murine endocrine model cannot establish a human hormonal outcome.
Read the primary studyCatalog options
Pack-level catalog data; lot-level controls remain document-specific.
Single-component peptide · 10 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Request by lot: CoA, HPLC purity and MS identity
Document availability is stated honestly and can vary by catalog variant or lot.
Analytical interpretation
Use the source-reviewed guide to separate chromatographic area purity, quantitative assay, LC-MS identity, composition and stability evidence before comparing variants or requesting a lot record.
Open the Quality & Documentation HubHPLC area ≠ assayA dominant peak does not establish target mass fraction.
Intact mass ≠ full sequenceIdentity strength depends on resolution and orthogonal evidence.
Counterions affect contentWater, salt form and solvents change the as-is composition.
Storage needs a data basisShipping practice is not the same as stability evidence.
Evidence map
Published studies and regulatory records, not customer testimonials or usage guidance.
The study is preclinical and does not define human benefit, dose or long-term safety.
View primary recordA murine endocrine model cannot establish a human hormonal outcome.
View primary recordThird-party publications selected for direct relevance.
Baar MP, et al. Cell. 2017. PMID 28340339.
Preclinical study. 2020. PMID 31959736.
Concise answers for researchers comparing identity, evidence and catalog variants.
FOXO4-DRI is an experimental peptide designed to disrupt FOXO4–p53 interaction in selected senescent cells. The widely cited evidence consists of cultured-cell work and mouse experiments, not validated human treatment outcomes.
Foundational cell and aged-mouse studies exist, but controlled human clinical evidence was not identified.
No. The cited records describe their own intervention, formulation, model and controls. They do not verify the identity, purity, sterility, safety or efficacy of a catalog lot.
A lot-specific COA, product specification sheet and analytical method summary can be requested where applicable.
Store at -20 °C, protected from light and moisture. After reconstitution, aliquot and avoid repeated freeze-thaw cycles. Confirm the applicable storage statement on the product-specific specification and lot documentation.
Knowledge center
Owned educational content connected to this family.
FOXO4-DRI is an experimental senolytic design supported by cultured-cell and mouse studies. Reports of restored fitness, renal function, testosterone or vascular function remain preclinical.
Updated September 8, 2026
FOXO4-DRI describes a D-retro-inverso peptide design intended to mimic the side-chain topology of a FOXO4 interaction segment while reversing backbone direction. It is not…
Updated September 8, 2026Knowledge tools
Move from this dossier into canonical evidence maps, verified status records, analytical interpretation and laboratory calculations.
Claims were checked against the linked primary publication, regulatory label or authoritative compound record. Published findings stay attached to their study model, formulation and route. Catalog identity and lot quality remain controlled by the applicable specification and lot-specific documents.
Technical procurement
Selected: F410 · 10 mg × 10 vials
Tell us what you need. Your enquiry will be routed to the appropriate contact for catalog numbers, availability and quotation details.
